Innovative antitumor Arfleyda® from R-Pharm received the Made in Russia certificate

R-Pharm Group, a leading Russian developer of pharmaceutical solutions, is launching the innovative antitumor Arfleyda®, a biosimilar of pembrolizumab, on the Russian market. The drug has received the Made in Russia certificate in the Reliability category, confirming its compliance with high quality standards and opening up opportunities for export promotion under the national brand. Arfleyda® is a humanized monoclonal antibody that selectively blocks the interaction between the PD-1 receptor and its ligands (PD-L1 and PD-L2). These molecules normally suppress the immune response, although PD-1 blockade removes this inhibition by activating cytotoxic T lymphocytes. As a result, the immune system begins to effectively attack tumor cells again. The drug was developed at the R-Pharm production site in Yaroslavl, and its production was established at the company's Yaroslavl plant. In the future, it is planned to organize production in Moscow as well. In 2024, Arfleyda® was included in the list of vital and essential drugs (VED), which confirms its importance for Russian healthcare. Russian Export Center (part of the VEB Group) is developing a comprehensive export promotion program under the Made in Russia international brand. The certificate is awarded to goods and services with improved characteristics and high quality. The certificate indicates the reliability of the manufacturer and safety of drug, which is especially important for promotion on international markets. The program is coordinated by the Ministry of Industry and Trade of Russia.